Antibody reduces harmful brain amyloid plaques in Alzheimer’s patients

Aducanumab, a new antibody has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer’s disease. These protein deposits in the brain are a …read more

Source:: Science